Randomized, Double Blind, a Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of CJ-50300 in Healthy Volunteers

Trial Profile

Randomized, Double Blind, a Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of CJ-50300 in Healthy Volunteers

Completed
Phase of Trial: Phase II/III

Latest Information Update: 18 Jun 2014

At a glance

  • Drugs CJ 50300 (Primary)
  • Indications Smallpox
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 26 Aug 2010 Status changed from recruiting to completed.
    • 29 Jun 2010 Results reported in Vaccine.
    • 04 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top